ChemicalBook >> CAS DataBase List >>Tucatinib

Tucatinib

CAS No.
937263-43-9
Chemical Name:
Tucatinib
Synonyms
Tucatinib;N4-(4-([1,2,4]triazolo[1,5-α]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine;4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-;CS-1710;ONT-380);6-diaMine;N4-(4-([1;Tacatinib;Tocatinib;Ttucatinib
CBNumber:
CB32616075
Molecular Formula:
C26H24N8O2
Molecular Weight:
480.52
MDL Number:
MFCD22380467
MOL File:
937263-43-9.mol
MSDS File:
SDS
Last updated:2024-08-01 14:21:03

Tucatinib Properties

Density 1.41±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMF:1.0(Max Conc. mg/mL);2.08(Max Conc. mM)
DMSO:49.0(Max Conc. mg/mL);101.97(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:2):0.33(Max Conc. mg/mL);0.69(Max Conc. mM)
form A crystalline solid
pka 6.61±0.70(Predicted)
color White to yellow
InChIKey SDEAXTCZPQIFQM-UHFFFAOYSA-N
SMILES N1=C2C(C=C(NC3=NC(C)(C)CO3)C=C2)=C(NC2=CC=C(OC3C=CN4N=CN=C4C=3)C(C)=C2)N=C1
FDA UNII 234248D0HH

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictograms
GHS07
Signal word  Warning
Hazard statements  H335-H315-H319
Precautionary statements  P261-P405-P305+P351+P338-P304+P340-P280
NFPA 704
0
1 0

Tucatinib price More Price(10)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
TRC D449790 ARRY-380 937263-43-9 25mg $1760 2021-12-16 Buy
ChemScene CS-3906 Tucatinib 99.82% 937263-43-9 100mg $450 2021-12-16 Buy
AK Scientific 8979DH Tucatinib 937263-43-9 25mg $590 2021-12-16 Buy
ChemScene CS-3906 Tucatinib 99.82% 937263-43-9 10mg $90 2021-12-16 Buy
ChemScene CS-3906 Tucatinib 99.82% 937263-43-9 50mg $250 2021-12-16 Buy
Product number Packaging Price Buy
D449790 25mg $1760 Buy
CS-3906 100mg $450 Buy
8979DH 25mg $590 Buy
CS-3906 10mg $90 Buy
CS-3906 50mg $250 Buy

Tucatinib Chemical Properties,Uses,Production

Description

Tucatinib is also known as ARRY-380 or Irbinitinib. ARRY-380 is an orally inhibitor of human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. It selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells. ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation. Therefore, ARRY-380 may be an alternative treatmentmethod for the treatment of HER2+ cancers.

Characteristics

Year of discovery: 2006
Year of introduction: 2020
Discovered by: Array BioPharma
Developed by: Array BioPharma
Primary targets: HER2
Binding type: I/II
Class: receptor tyrosine kinase
Treatment: HER2-positive breast cancer
Other names: ONT-380, ARRY-380
Oral bioavailability = not reported
Elimination half-life = 5.4 hours
Protein binding = 97%

Uses

Tucatinib, a highly selective HER2 inhibitor, was approved in 2020 as a combination therapy with trastuzumab and capecitabine for the treatment of patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

brand name

TukysaTM

Side effects

Tukysa (tucatinib) is a brand-name prescription medication. The Active ingredient is tucatinib. Serious side effects can include diarrhoea, liver damage, and allergic reactions. Mild side effects can occur with Tukysa use. This list doesn’t include all possible mild side effects of the drug. Mild side effects that have been reported with Tukysa include nausea and vomiting, fatigue, reduced appetite, weight loss, joint pain; peripheral neuropathy (nerve damage that causes tingling, numbness, or weakness in your arms, hands, legs, or feet); abdominal pain; headache; skin rash; nosebleeds; anemia (low level of red blood cells); stomatitis; hand-foot syndrome.

storage

Store at -20°C

Mode of action

Tucatinib binds to tyrosine kinase (an enzyme) of HER2, reducing PI3-kinase and MAP-kinase signaling. In vitro, tucatinib inhibits phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, and showed anti-tumor activity in HER2 expressing tumor cells. In vivo, tucatinib inhibited the growth of HER2 expressing tumors. The combination of tucatinib and trastuzumab showed increased anti-tumor activity in vitro and in vivo compared to either drug alone.

References

[1] PATRICE A LEE. In VivoActivity of ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2 in Combination with Trastuzumab, Docetaxel or Bevacizumab.[J]. Cancer research, 2009, 69 1: 5104-5104. DOI:10.1158/0008-5472.SABCS-09-5104.
[2] S. MOULDER. Abstract A143: ARRY-380, a selective HER2 inhibitor: From drug design to clinical evaluation.[J]. Molecular Cancer Therapeutics, 2011, 10 1. DOI:10.1158/1535-7163.TARG-11-A143.
[3] V. DINKEL. Abstract 852: ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice[J]. Cancer research, 2012, 72 1: 852-852. DOI:10.1158/1538-7445.AM2012-852.
[4] KOCIE?SKI P. Synthesis of Tucatinib[J]. Synfacts, 2019, 24 1: 0965. DOI:10.1055/s-0039-1690496.
[5] RASHMI K MURTHY. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.[J]. New England Journal of Medicine, 2020, 382 7: 597-609. DOI:10.1056/NEJMoa1914609.
[6] RASHMI MURTHY. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.[J]. Lancet Oncology, 2018: 880-888. DOI:10.1016/S1470-2045(18)30256-0.

1429755-58-7
937263-43-9
Synthesis of Tucatinib from Tucatinib N-1

Tucatinib Preparation Products And Raw materials

Global( 199)Suppliers
Supplier Tel Email Country ProdList Advantage
Zhengzhou Anhuida Chemical Co., Ltd
+8615903659408 admin@ahdchem.com China 297 58
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
+86-18600796368 +86-18600796368 sales@sjar-tech.com China 251 58
Zhengzhou Anbu Chem Co.,Ltd
+86-0371-88006763; +8615988602810 sales@anbuchem.com China 3000 58
Hangzhou Hyper Chemicals Limited
+86-0086-57187702781 +8613675893055 info@hyper-chem.com China 295 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512 info@tianfuchem.com China 21667 55
Nanjing Finetech Chemical Co., Ltd.
025-85710122 17714198479 sales@fine-chemtech.com CHINA 885 55
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795 ivan@atkchemical.com China 32836 60
TianYuan Pharmaceutical CO.,LTD
+86-755-23284190 13684996853 sales@tianpharm.com CHINA 304 58
Shenzhen Nexconn Pharmatechs Ltd
+86-755-89396905 +86-15013857715 admin@nexconn.com China 10311 58
BOC Sciences
+1-631-485-4226 inquiry@bocsci.com United States 19553 58

Related articles

  • Synthesis of Tucatinib
  • Tucatinib was synthesised in a two-step reaction by an aniline fragment. Tucatinib is an orally bioavailable tyrosine kinase i....
  • Jan 8,2024

View Lastest Price from Tucatinib manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Tucatinib pictures 2024-09-14 Tucatinib
937263-43-9
US $0.00-0.00 / kg 1kg 99%,single impurity<0.1 1 ton Nanjing Fred Technology Co., Ltd
Tucatinib pictures 2024-09-11 Tucatinib
937263-43-9
US $0.00 / g 1g More Than 99% 100kg/Month BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
Tucatinib pictures 2024-09-07 Tucatinib
937263-43-9
US $0.00-0.00 / KG 1KG EP/USP 1 ton Hangzhou Hyper Chemicals Limited
  • Tucatinib pictures
  • Tucatinib
    937263-43-9
  • US $0.00-0.00 / kg
  • 99%,single impurity<0.1
  • Nanjing Fred Technology Co., Ltd
  • Tucatinib pictures
  • Tucatinib
    937263-43-9
  • US $0.00 / g
  • More Than 99%
  • BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
  • Tucatinib pictures
  • Tucatinib
    937263-43-9
  • US $0.00-0.00 / KG
  • EP/USP
  • Hangzhou Hyper Chemicals Limited

Tucatinib Spectrum

ONT-380) N4-(4-([1 N6-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4,6-quinazolinediamine Irbinitinib Irbinitinib(ARRY380) (R)-N6-(4-Methyl-4 5-dihydrooxazol-2-yl)-N4-(3-Methyl-4-(thiazol-2-ylMethoxy)phenyl)quinazoline-4 6-diaMine 4-diMethyl-4 5-a]pyridin-7-yloxy)-3-Methylphenyl)-N6-(4 5-dihydrooxazol-2-yl)quinazoline-4 ARRY-380;IRBINITINIB [INN]; SCHEMBL1193050; ONT-380; Irbinitinib [INN] Tucatinib(ARRY-380, ONT-380) Irbinitinib (Tucatinib) Tucatinib (Irbinitinib,ARRY-380) Tacatinib N6-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)Chemicalbook-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4,6-quinazolinediamine Irbinitirnib(ARRY-380) Tukysa/Tucatinib/ONT-380 Tocatinib SCHEMBL1193050 CS-1710 IRBINITINIB (ARRY-380; ONT-380) Irbinitinib (ARRY-380,Tucatinib,ONT 380) N4-(4-([1,2,4]triazolo[1,5-α]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Tucatinib 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]- Ttucatinib 13C6]-Tucatinib 2H8]-Tucatinib ONT-380,tucatinib) N4-(4-([1,2,4]Triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine Deterenol Monomer Tucatinib API Irbinitinib (ONT-380) Tucatinib (Irbinitinib, ONT-380) 937263-43-9 Inhibitors API